Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Published byOwen Morgan Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or."— Presentation transcript:

1 Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or type 2 diabetes (T2D). Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or type 2 diabetes (T2D). Circulating vaspin in groups of NGT (n = 20), IGT (n = 20), and type 2 diabetes (n = 20). Data are means ± SE. *P < 0.05 between baseline and after 4 weeks of intensive physical training. □, basal; ▪, after training. Byung-Soo Youn et al. Diabetes 2008;57: ©2008 by American Diabetes Association

Download ppt "Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or."

Similar presentations

Questions 48 - 50 Diabetes. 48. NIDDM response The figure below shows the ‘normal’ response of blood glucose (solid line) and insulin (dashed line) concentrations.

Questions Diabetes. 48. NIDDM response The figure below shows the ‘normal’ response of blood glucose (solid line) and insulin (dashed line) concentrations.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26:2433-41. Centers for Disease Control.

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Effects of highly concentrated SFN provided as BSE in T2D patients

Effects of highly concentrated SFN provided as BSE in T2D patients
John Widger, Sarath Ranganathan, Philip J. Robinson 

John Widger, Sarath Ranganathan, Philip J. Robinson 
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Insulin resistance in African Americans

Insulin resistance in African Americans
(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.
A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.
Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.
Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.
A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.
A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Similar presentations

Ads by Google